MA31857B1 - N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci - Google Patents

N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci

Info

Publication number
MA31857B1
MA31857B1 MA32849A MA32849A MA31857B1 MA 31857 B1 MA31857 B1 MA 31857B1 MA 32849 A MA32849 A MA 32849A MA 32849 A MA32849 A MA 32849A MA 31857 B1 MA31857 B1 MA 31857B1
Authority
MA
Morocco
Prior art keywords
phenyl
substituted
pyrrolidinylmethylpyrrolidine
amides
therapeutic use
Prior art date
Application number
MA32849A
Other languages
English (en)
Inventor
Werngard Czechtizky
Zhongli Gao
William J Hurst
Lothar Schwink
Siegfried Stengelin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31857B1 publication Critical patent/MA31857B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE SÉRIE D'AMIDES DE N-PHÉNYL-PYRROLIDINYLMÉTHYLPYRROLIDINE SUBSTITUÉS DE FORMULE (I) TELS QUE DÉCRITS ICI. PLUS PARTICULIÈREMENT, LES COMPOSÉS DE LA PRÉSENTE INVENTION SONT DES MODULATEURS DES RÉCEPTEURS H3 ET SONT, PAR CONSÉQUENT, UTILES COMME AGENTS PHARMACEUTIQUES, EN PARTICULIER DANS LE TRAITEMENT ET/OU LA PRÉVENTION D'UNE VARIÉTÉ DE MALADIES MODULÉES PAR DES RÉCEPTEURS H3 COMPRENANT DES MALADIES ASSOCIÉES AVEC LE SYSTÈME NERVEUX CENTRAL. DE PLUS, CETTE INVENTION DÉCRIT ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION D'AMIDES DE N-PHÉNYL-PYRROLIDINYLMÉTHYLPYRROLIDINE SUBSTITUÉS ET D'INTERMÉDIAIRES DE CEUX-CI.
MA32849A 2007-10-17 2010-05-17 N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci MA31857B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98060207P 2007-10-17 2007-10-17

Publications (1)

Publication Number Publication Date
MA31857B1 true MA31857B1 (fr) 2010-11-01

Family

ID=40137955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32849A MA31857B1 (fr) 2007-10-17 2010-05-17 N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci

Country Status (20)

Country Link
US (1) US8227504B2 (fr)
EP (1) EP2205558B1 (fr)
JP (1) JP5377504B2 (fr)
KR (1) KR20100092443A (fr)
CN (1) CN101903342B (fr)
AU (1) AU2008312636B2 (fr)
BR (1) BRPI0818766A2 (fr)
CA (1) CA2702834C (fr)
DK (1) DK2205558T3 (fr)
ES (1) ES2392122T3 (fr)
HK (1) HK1146055A1 (fr)
IL (1) IL205000A0 (fr)
MA (1) MA31857B1 (fr)
MX (1) MX2010004003A (fr)
MY (1) MY150210A (fr)
NZ (1) NZ584691A (fr)
PT (1) PT2205558E (fr)
RU (1) RU2477721C2 (fr)
WO (1) WO2009052063A1 (fr)
ZA (1) ZA201002113B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702467C (fr) 2007-10-17 2012-11-27 Sanofi-Aventis Carboxamides de n-phenyl-bipyrrolidine substitues et leur utilisation therapeutique
RU2477719C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение
DK2215058T3 (da) 2007-10-17 2012-03-12 Sanofi Sa Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
AR074466A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
TW201202251A (en) 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
AR081498A1 (es) 2010-05-11 2012-09-19 Sanofi Aventis Derivados de n-alquil -y n-acil-tetrahidroisoquinolina sustituidos, preparacion y su uso terapeutico de los mismos
AR081382A1 (es) * 2010-05-11 2012-08-29 Sanofi Aventis Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central.
RU2562461C1 (ru) * 2014-04-30 2015-09-10 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Спин-меченое производное кинуренина и способ его получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
CA2504272A1 (fr) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines et phenylpyrrolidines utilisees comme modulateurs du recepteur h3 de l'histamine
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
JP5052497B2 (ja) * 2005-03-17 2012-10-17 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体アンタゴニストとしてのピロリジン誘導体
CN101151244B (zh) * 2005-04-01 2014-09-03 伊莱利利公司 组胺h3受体活性剂、制备和治疗用途
WO2007005503A1 (fr) * 2005-07-01 2007-01-11 Eli Lilly And Company Agents recepteurs de l'histamine h3, preparation et utilisations therapeutiques
AU2006308167A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
TW200800908A (en) * 2006-02-15 2008-01-01 Sanofi Aventis Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CA2702467C (fr) 2007-10-17 2012-11-27 Sanofi-Aventis Carboxamides de n-phenyl-bipyrrolidine substitues et leur utilisation therapeutique
RU2477719C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение
DK2215058T3 (da) 2007-10-17 2012-03-12 Sanofi Sa Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf

Also Published As

Publication number Publication date
EP2205558B1 (fr) 2012-07-25
PT2205558E (pt) 2012-11-02
AU2008312636A1 (en) 2009-04-23
JP5377504B2 (ja) 2013-12-25
CN101903342B (zh) 2012-11-21
MY150210A (en) 2013-12-13
EP2205558A1 (fr) 2010-07-14
DK2205558T3 (da) 2012-11-05
RU2477721C2 (ru) 2013-03-20
CA2702834C (fr) 2013-01-15
HK1146055A1 (en) 2011-05-13
RU2010119530A (ru) 2011-11-27
KR20100092443A (ko) 2010-08-20
AU2008312636B2 (en) 2013-03-14
CN101903342A (zh) 2010-12-01
IL205000A0 (en) 2010-11-30
CA2702834A1 (fr) 2009-04-23
US8227504B2 (en) 2012-07-24
NZ584691A (en) 2011-09-30
BRPI0818766A2 (pt) 2015-04-14
WO2009052063A1 (fr) 2009-04-23
ES2392122T3 (es) 2012-12-04
US20100173898A1 (en) 2010-07-08
JP2011500694A (ja) 2011-01-06
ZA201002113B (en) 2010-12-29
MX2010004003A (es) 2010-04-30

Similar Documents

Publication Publication Date Title
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA29807B1 (fr) Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
TNSN08099A1 (fr) 1-h-imidazopyridines a substituant hydroxy et procedes
MA30084B1 (fr) Triazolopyridazines en tant que modulateurs de la tyrosine kinase
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
TNSN05317A1 (fr) Ligands des recepteurs de cannabinoides et leurs utilisations
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
MA31766B1 (fr) Composés organiques
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines